Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 11;14(4):1177.
doi: 10.3390/jcm14041177.

Clinical Outcomes for Nasopharyngeal Cancer in Non-Asian Patients: A Single-Center Experience

Renata Zahu  1   2 , Daniela Urian  2 , Vlad Manolescu  2 , Andrei Ungureanu  2 , Carmen Bodale  2 , Alexandru Iacob  2 , Stefan Cristian Vesa  3 , Cristina Tiple  4 , Gabriel Kacso  1   2
Affiliations

Clinical Outcomes for Nasopharyngeal Cancer in Non-Asian Patients: A Single-Center Experience

Renata Zahu et al. J Clin Med. .

Abstract

Background/Objectives: According to Globocan, Romania has the highest incidence of nasopharyngeal cancer (NPC) in Europe. Our objective was to evaluate the survival data for a cohort of non-Asian patient population treated with curative intent at a tertiary cancer center in Romania. Methods: We retrospectively analyzed 161 patients with histologically proven, non-metastatic NPC treated at our institution between October 2014 and December 2021 with intensity modulated arc radiotherapy (IMRT) with or without neoadjuvant or concomitant chemotherapy according to the stage of the disease. Kaplan-Meier estimates of overall, disease-free, locoregional relapse free and distant metastasis free survival were calculated. The log-rank test was used to determine significant prognostic determinants of overall and disease-free survival. Results: The median age was 50 years (range 19-80), 88% had nonkeratinizing undifferentiated carcinoma. Epstein Barr virus status was not evaluated routinely. 42.2% of patients were stage III and 46% stage IVA disease. Induction chemotherapy was prescribed for 72.7% of patients and 89.4% received concurrent chemotherapy. After a median follow up of 44 months (range: 3.6, 104.7 months), the estimated 3 years overall, disease free, locoregional relapse free and distant metastasis free survival of the entire cohort were 82.6%, 73.3%, 83.2% and 86.3% respectively. On testing interactions, concomitant chemotherapy offered significant survival benefit (HR-0.287; 95% CI 0.137-0.603; p = 0.001) and cumulative Cisplatin dose of more than 100 mg/mp was statistically significant for survival (HR-0.350;95% CI 0.157-0.779; p = 0.01) Conclusions: This is the largest retrospective series of nasopharyngeal cancer from Romania reporting survival data. Despite the high percentage of advanced stage disease our data shows very good disease control. Compliance to optimal concomitant chemotherapy should represent a priority in clinical practice in a non-Asian patient population.

Keywords: chemotherapy; nasopharynx cancer; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
(a) Overall survival; (b) Disease free survival; (c) Locoregional relapse free survival; (d) Distant metastasis free survival.
Figure 1
Figure 1
(a) Overall survival; (b) Disease free survival; (c) Locoregional relapse free survival; (d) Distant metastasis free survival.
Figure 2
Figure 2
Overall survival according to Cisplatin administration (a) Concomitant Cisplatin versus No Cisplatin (b). High dose, three weekly Cisplatin versus weekly Cisplatin.
See this image and copyright information in PMC

References

    1. Chang E.T., Chang E.T., Ye W., Ye W., Zeng Y.-X., Zeng Y.-X., Adami H.-O., Adami H.-O. The Evolving Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiol. Biomark. Prev. 2021;30:1035–1047. doi: 10.1158/1055-9965.EPI-20-1702. - DOI - PubMed
    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Song Y., Cheng W., Li H., Liu X. The global, regional, national burden of nasopharyngeal cancer and its attributable risk factors (1990–2019) and predictions to 2035. Cancer Med. 2022;11:4310–4320. doi: 10.1002/cam4.4783. - DOI - PMC - PubMed
    1. Su Z.Y., Siak P.Y., Leong C.-O., Cheah S.-C. The role of Epstein–Barr virus in nasopharyngeal carcinoma. Front. Microbiol. 2023;14:1116143. doi: 10.3389/fmicb.2023.1116143. - DOI - PMC - PubMed
    1. Patel V.J., Chen N., Resto V.A. Racial and Ethnic Disparities in Nasopharyngeal Cancer Survival in the United States: A SEER Study. Otolaryngol.–Head Neck Surg. 2017;156:122–131. doi: 10.1177/0194599816672625. - DOI - PubMed

LinkOut - more resources